BioWisdom Limited

BioWisdom Limited

June 05, 2007 04:00 ET

BioWisdom Announces Mitsubishi Pharma Corporation to use BioWisdom KnowledgeScan™

CAMBRIDGE, UNITED KINGDOM--(Marketwire - June 5, 2007) - BioWisdom Limited (BioWisdom), a leader in the development and application of Intelligence Networks for the pharmaceutical industry, today announced that Mitsubishi Pharma Corporation has signed an agreement for BioWisdom KnowledgeScan.

BioWisdom KnowledgeScan™ uses BioWisdom's powerful Sofia platform to provide unbiased and comprehensive Intelligence to support healthcare-related decision-making for project teams. The service provides a rapid and systematic analysis of available data and is carried out by BioWisdom's healthcare analysts.

"We are delighted to have this opportunity to work with Mitsubishi Pharma" said Julie Barnes, CSO of BioWisdom. "We see this as further confirmation of the application of BioWisdom's Sofia technology and indeed BioWisdom KnowledgeScan to support business-critical decision making."

Notes to Editors


BioWisdom delivers intelligence for the Healthcare Industry and helps clients to navigate the complex scientific and commercial issues involved in developing successful healthcare products. The company provides a powerful suite of software tools for the acquisition, integration, visualization and high value analysis of healthcare intelligence. The BioWisdom team combines extensive experience of the pharmaceutical and biotechnology industries with proven expertise in life science software development.

For further information please visit


Mitsubishi Pharma Corporation is a global research-driven pharmaceutical company targeting the therapeutic areas of cardiovascular and metabolic diseases, psychiatric and central nervous system diseases, immunological and respiratory diseases, and cancer and hepatic diseases. This company was founded by the merger between former Welfide Corporation and Mitsubishi-Tokyo Pharmaceuticals, Inc., on October 1, 2001. Mitsubishi Pharma Corporation has established a strong drug discovery infrastructure to engage in the development of innovative new drugs.

For further information please visit

Contact Information